Evidence map›Paper›PMID 21844097›Full record

ArticleDiabetes2011

Vascular dysfunction in experimental diabetes is improved by pentaerithrityl tetranitrate but not isosorbide-5-mononitrate therapy.

Swenja Schuhmacher, Matthias Oelze, Franziska Bollmann, Hartmut Kleinert, Christian Otto, Tjebo Heeren, Sebastian Steven, Michael Hausding, Maike Knorr, Andrea Pautz and 6 more

Open access · bronzeAbstract read
In one paragraph

Article in Diabetes, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.

0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed
4.9field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

42 citing papers in PubMed, 90 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Exogenous NO Therapy for the Treatment and Prevention of Atherosclerosis.International journal of molecular sciences · 2020
    Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Oxidative Stress in Atherosclerosis.Current atherosclerosis reports · 2017
    Review
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 2 institutions in 1 country.

Swenja Schuhmacher2nd Medical Clinic, Department of Cardiology, Medical Centerof the Johannes Gutenberg University, Mainz, Germany.
Matthias Oelze
Franziska Bollmann
Hartmut Kleinert
Christian Otto
Tjebo Heeren
Sebastian Steven
Michael Hausding
Maike Knorr
Andrea Pautz
Kurt Reifenberg
Eberhard Schulz
Tommaso Gori
Philip Wenzel
Thomas Münzel
Andreas Daiber
University Medical Center of the Johannes Gutenberg University Mainz · DEJohannes Gutenberg University Mainz · DE

Funding

Wellcome Trust 090532
6 · The paper itself

Abstract

objectiveDiabetes is associated with vascular oxidative stress, activation of NADPH oxidase, and uncoupling of nitric oxide (NO) synthase (endothelial NO synthase [eNOS]). Pentaerithrityl tetranitrate (PETN) is an organic nitrate with potent antioxidant properties via induction of heme oxygenase-1 (HO-1). We tested whether treatment with PETN improves vascular dysfunction in the setting of experimental diabetes. RESEARCH DESIGN AND

methodsAfter induction of hyperglycemia by streptozotocin (STZ) injection (60 mg/kg i.v.), PETN (15 mg/kg/day p.o.) or isosorbide-5-mononitrate (ISMN; 75 mg/kg/day p.o.) was fed to Wistar rats for 7 weeks. Oxidative stress was assessed by optical methods and oxidative protein modifications, vascular function was determined by isometric tension recordings, protein expression was measured by Western blotting, RNA expression was assessed by quantitative RT-PCR, and HO-1 promoter activity in stable transfected cells was determined by luciferase assays.

resultsPETN, but not ISMN, improved endothelial dysfunction. NADPH oxidase and serum xanthine oxidase activities were significantly reduced by PETN but not by ISMN. Both organic nitrates had minor effects on the expression of NADPH oxidase subunits, eNOS and dihydrofolate reductase (Western blotting). PETN, but not ISMN, normalized the expression of GTP cyclohydrolase-1, extracellular superoxide dismutase, and S-glutathionylation of eNOS, thereby preventing eNOS uncoupling. The expression of the antioxidant enzyme, HO-1, was increased by STZ treatment and further upregulated by PETN, but not ISMN, via activation of the transcription factor NRF2.

conclusionsIn contrast to ISMN, the organic nitrate, PETN, improves endothelial dysfunction in diabetes by preventing eNOS uncoupling and NADPH oxidase activation, thereby reducing oxidative stress. Thus, PETN therapy may be suited to treat patients with cardiovascular complications of diabetes.

Indexed as

AnimalsBlood GlucoseDiabetes Mellitus, ExperimentalEndothelium, VascularGene SilencingGTP CyclohydrolaseHeme Oxygenase-1Isosorbide DinitrateMaleNADPH OxidasesOxidative StressPentaerythritol TetranitrateRatsRats, WistarReactive Oxygen SpeciesVasoconstrictionBlood GlucoseGTP CyclohydrolaseHeme Oxygenase-1isosorbide-5-mononitrateIsosorbide DinitrateNADPH OxidasesPentaerythritol TetranitrateReactive Oxygen SpeciesVasodilator AgentsXanthine Oxidase

Identifiers

PMID21844097
PMCPMC3178293
OpenAlexW2147136957

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.